Literature DB >> 2917356

Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies.

P G Natali1, A Bigotti, M R Nicotra, R M Nardi, A Delovu, O Segatto, S Ferrone.   

Abstract

The reactivity of 12 surgically removed uveal melanoma lesions with monoclonal antibodies (MoAb) to 14 membrane-bound and 2 cytoplasmic cutaneous melanoma-associated antigens (MAA), to the 2 subunits of HLA Class I antigens and to the gene products of the HLA-D region was compared with that of cutaneous melanoma lesions and correlated with their histiotype. The membrane-bound determinants defined by the anti-Mr 92,000 and 45,000 MAA MoAb TP39.1, anti-Mr 110,000 MAA MoAb M111, anti-Mr 118,000 MAA MoAb TP36.1, anti-Mr 115,000 MAA MoAb 345.134, anti-ICAM-1 MoAb CL203.4 and anti-Mr 31,000 MAA MoAb M2590, and the cytoplasmic determinants defined by the anti-MAA MoAb 465.12 and 2G-10 display a distribution in uveal melanoma lesions similar to that in cutaneous melanoma lesions. On the other hand, membrane-bound determinants defined by the anti-Mr 100,000 MAA MoAb 376.96, anti-9-O-acetyl-GD3 ganglioside MoAb ME311 and anti-GD2-GD3 ganglioside MoAb ME361 were not detected in the uveal melanoma lesions tested. Furthermore, the membrane-bound determinants defined by the anti-GD3 MoAb R24, anti-nerve growth factor receptor MoAb ME20.4, anti-Mr 97,000 MAA MoAb 140.240, anti-carcinoembryonic antigen MoAb B1.1 and anti-HMW-MAA 149.53, 225.28, and 763.74 have a markedly lower expression in uveal than in cutaneous melanoma lesions. Incubation of uveal melanoma lesions with the pool of the MoAb 149.53, 225.28, and 763.74 recognizing distinct and spatially distant determinants of the HMW-MAA increased the intensity of staining of six lesions and stained four lesions which were not stained by the individual monoclonal antibodies. The distribution of HLA Class I antigens in uveal melanoma lesions resembles that in cutaneous melanoma lesions, since they are expressed in all the lesions of the mixed and epithelioid type but were not detected in those of the spindle type, i.e., the counterparts of nevocellular nevi. HLA Class II antigens are expressed with a lower frequency in uveal than in cutaneous melanoma lesions, since they were detected only in 2 of the 12 lesions. One of them is of the mixed type and the other one of the epithelioid type. Besides HLA antigens the determinants defined by the anti-carcinoembryonic MoAb B1.1, anti-ICAM-1 MoAb CL203.4, and anti-GD3 MoAb R24 displayed a differential distribution in the different histiotypes of uveal melanoma, since they are preferentially expressed in lesions of the mixed and epithelioid type.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917356

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

2.  HLA expression in a primary uveal melanoma, its cell line, and four of its metastases.

Authors:  D J Blom; L R Schurmans; I De Waard-Siebinga; D De Wolff-Rouendaal; J E Keunen; M J Jager
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

3.  Immunoscintigraphy for ocular melanoma: a reliable diagnostic technique?

Authors:  K U Loeffler; P Bräutigam; J C Simon; S R Althauser; C Wuttig; H Witschel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-02       Impact factor: 3.117

Review 4.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

5.  Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results.

Authors:  D F Schaling; J P van der Pol; M J Jager; M J van Kroonenburgh; J A Oosterhuis; D J Ruiter
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

6.  Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin.

Authors:  M Yamamoto; H Takahashi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results.

Authors:  G Modorati; R Brancato; G Paganelli; P Magnani; R Pavoni; F Fazio
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

Review 8.  Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy.

Authors:  Sophie Groux-Degroote; Philippe Delannoy
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.

Authors:  Mahiuddin Ahmed; Yehuda Goldgur; Jian Hu; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

10.  High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.

Authors:  T J de Vries; D Trancikova; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.